Tech Transfer Roundup: Oncology Deals Focus On CAR-T Innovations, ADCs, DNA Damage Response
Cancer deals involve City of Hope/Chimeric, CARISMA/NYU, Sorrento/Mayo Clinic, Rain/Drexel, Diaprost/Memorial Sloan Kettering, Alkido/University of Kentucky. Plus, research collaborations in brief.
You may also be interested in...
Otsuka subsidiary Astex plans filing in MDS by year-end for first oral decitabine product on the back of positive Phase III comparative results.
No disease is too small or too large for SpringWorks, which spun out Pfizer with four mid-/late-stage compounds to develop drugs in indications where patients have no good treatment options.
The rare disease-focused firm will pay $90m up front to acquire Orphan Technologies and its Phase I/II enzyme replacement therapy for homocystinuria. Earnouts up to $427m are possible as well.